Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Drug PIC

MSD’s KEYTRUDA Wins NMPA Approval for Perioperative Treatment of Resectable Locally Advanced HNSCC in China

Fineline Cube Sep 4, 2026
Company Deals PIC

Typewriter Therapeutics Raises USD 56 Million Series A to Advance TPRT RNA Gene Insertion Platform for In Vivo CAR-T and Liver Diseases

Fineline Cube Sep 4, 2026
Company Deals Drug PIC

Takeda and Belief BioMed End Xinjiuning Commercialization Partnership; Belief BioMed to Advance Gene Therapy Independently

Fineline Cube Sep 4, 2026
Company Deals Drug PIC

Keymed Biosciences Grants Aeira Exclusive Rights to Stapokibart Across 18 Southeast and Central Asia Markets, Securing High Double‑Digit Royalties

Fineline Cube Sep 3, 2026
Company Deals PIC

Medtronic Invests USD 700 Million in Cornerstone Robotics, Wins Distribution Rights for Sentire Endoscopic Surgical Robot Outside the U.S.

Fineline Cube Sep 3, 2026
Company Drug PIC

MSD’s KEYTRUDA Wins NMPA Approval for Perioperative Treatment of Resectable Locally Advanced HNSCC in China

Fineline Cube Sep 4, 2026
Company Drug PIC

MSD’s KEYTRUDA Wins NMPA Approval for Perioperative Treatment of Resectable Locally Advanced HNSCC in China

Fineline Cube Sep 4, 2026
Policy / Regulatory

China’s 2026 NHSA Drug Negotiations Open Sept 5 with Parallel Commercial Insurance Innovative Drug Catalog Talks

Fineline Cube Sep 4, 2026
Company

BeiGene Launches Flagship US Facility in New Jersey to Expand Oncology R&D and Manufacturing

Fineline Cube Jul 24, 2024

BeiGene (NASDAQ: BGNE; HKG: 6160; SHA: 688235), a global biotechnology company, has announced the inauguration...

Company Drug

Bayer’s BAY 3375968 Receives NMPA Approval for Clinical Trial in Advanced Solid Tumors

Fineline Cube Jul 24, 2024

Bayer AG (ETR: BAYN), a multinational pharmaceutical giant based in Germany, has received clinical trial...

Company Drug

Chipscreen’s HDAC Inhibitor Chidamide to be Tested in Combination Therapy for CRC by NMPA

Fineline Cube Jul 24, 2024

Shenzhen Chipscreen Biosciences Co., Ltd (SHA: 688321), a biopharmaceutical company based in China, has received...

Company Deals

Anhui Anke Biotechnology Receives NMPA Approval for Clinical Trial of HPV-Targeting mRNA Drug AFN0328

Fineline Cube Jul 24, 2024

China-based Anhui Anke Biotechnology (Group) Co., Ltd (SHE: 300009) has announced that it has received...

Company Deals

Novogene and Becton, Dickinson Partner to Advance Single Cell Sequencing Technologies

Fineline Cube Jul 24, 2024

Novogene (SHA: 688315), a genomic services and solutions provider based in Beijing and operating globally,...

Company Deals

Shanghai Desano and Chongqing Kangfude Partner to Establish Peptide Drug Production Base in China

Fineline Cube Jul 24, 2024

Shanghai Desano Biopharmaceutical Co., Ltd, a leading biopharmaceutical company based in China, has entered into...

Company Deals

TowardPi Medical Partners with OCULUS Iberia to Introduce Advanced OCTA Technology to Spain

Fineline Cube Jul 24, 2024

TowardPi (Beijing) Medical Technology Ltd, a Chinese medical technology company specializing in ophthalmic imaging, has...

Company Drug

ViiV Healthcare’s Dovato Shows Non-Inferior Efficacy and Less Weight Gain in Pivotal PASO DOBLE Study

Fineline Cube Jul 24, 2024

ViiV Healthcare, the HIV-focused subsidiary majority-owned by GSK with Pfizer and Shionogi as shareholders, has...

Company

Pfizer Launches SGD 1 Billion API Plant Expansion in Singapore, Creating 250 New Jobs

Fineline Cube Jul 24, 2024

Pfizer Inc., (NYSE: PFE) a leading global pharmaceutical company, has announced the opening of an...

Policy / Regulatory

China’s NHSA Updates DRG/DIP Payment Reform Program with New Exclusion Mechanisms and Timelines

Fineline Cube Jul 23, 2024

The National Healthcare Security Administration (NHSA) in China has issued a notification outlining several updates...

Company Drug

Jiangsu Hansoh’s Loxenatide Matches Dapagliflozin in Diabetes Nephropathy Clinical Trial

Fineline Cube Jul 23, 2024

Jiangsu Hansoh Pharmaceutical Co., Ltd, a leading pharmaceutical company based in China, has published the...

Company Deals

Innovax Biotech and GSK Terminate Collaboration on Next-Generation HPV Vaccine

Fineline Cube Jul 23, 2024

Xiamen Innovax Biotech Co., Ltd., a Chinese biopharmaceutical company, and GlaxoSmithKline (GSK, NYSE: GSK), a...

Company Drug

China’s NMPA Considers Breakthrough Designations for Xiangxue and Innostellar’s Therapies

Fineline Cube Jul 23, 2024

Xiangxue Pharmaceutical Co., Ltd (SHE: 300147) and Innostellar Biotherapeutics Co., Ltd have both been noted...

Company Deals

Aligos Therapeutics and Xiamen Amoytop Biotech Partner to Test Hepatitis B Combination Therapy

Fineline Cube Jul 23, 2024

Aligos Therapeutics Inc. (NASDAQ: ALGS), a San Francisco-based biotechnology company, has announced a clinical trial...

Company Drug

Johnson & Johnson Pursues FDA Approval for Spravato as Monotherapy for Treatment-Resistant Depression

Fineline Cube Jul 23, 2024

Johnson & Johnson (J&J, NYSE: JNJ), a leading global healthcare company, is pursuing expanded approval...

Company Policy / Regulatory

WuXi AppTec Spends Over USD 360,000 on US Lobbying Amid Biosecure Act Deliberations

Fineline Cube Jul 23, 2024

Endpoints News has reported that WuXi AppTec Co., Ltd, (SHA: 603259) a China-based Contract Development...

Company

Sino Biopharm’s Subsidiary invoX Restructures, Focusing on CD137/PD-L1 Molecule FS222

Fineline Cube Jul 23, 2024

UK-based biotechnology company invoX, an international subsidiary established by China-based Sino Biopharmaceutical Group in 2021,...

Company Deals

China’s Triastek and Germany’s BioNTech Join Forces for 3D Printed Oral Therapeutics

Fineline Cube Jul 23, 2024

Triastek Inc., a China-based pharmaceutical company specializing in 3D printing technology, has entered into a...

Company Drug

RemeGen’s Telitacicept Earns Full NMPA Approval for RA Treatment and PMN Clinical Study Green Light

Fineline Cube Jul 23, 2024

RemeGen (HKG: 9995), a biopharmaceutical company based in China, has announced that the National Medical...

Policy / Regulatory

NMPA Suspends Import and Sale of SAMO S.p.A Knee and Hip Prosthesis Systems

Fineline Cube Jul 23, 2024

The National Medical Products Administration (NMPA) has issued a notice to suspend the import, sale,...

Posts pagination

1 … 376 377 378 … 716

Recent updates

  • MSD’s KEYTRUDA Wins NMPA Approval for Perioperative Treatment of Resectable Locally Advanced HNSCC in China
  • China’s 2026 NHSA Drug Negotiations Open Sept 5 with Parallel Commercial Insurance Innovative Drug Catalog Talks
  • Trinomab’s Retavibart Wins NMPA Priority Approval as RSV Prevention Monoclonal Antibody Xinduotuo
  • Xuanzhu Biopharmaceutical Signs Thailand Commercial Agreement with Innobic and ZaoAn for Bireociclib
  • Betta’s Ensartinib Wins NMPA Approval for Third Indication as Adjuvant Therapy in ALK-Positive NSCLC
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug PIC

MSD’s KEYTRUDA Wins NMPA Approval for Perioperative Treatment of Resectable Locally Advanced HNSCC in China

Policy / Regulatory

China’s 2026 NHSA Drug Negotiations Open Sept 5 with Parallel Commercial Insurance Innovative Drug Catalog Talks

Company Drug

Trinomab’s Retavibart Wins NMPA Priority Approval as RSV Prevention Monoclonal Antibody Xinduotuo

Company Deals

Xuanzhu Biopharmaceutical Signs Thailand Commercial Agreement with Innobic and ZaoAn for Bireociclib

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2026 | Fineline Information & Technology | BlogData by Themeansar.